

The Biotech Growth Trust PLC



Portfolio Manager



Geoffrey Hsu

Information as at 30 November 2020

www.biotechgt.com


[@BiotechGT](https://twitter.com/BiotechGT)

Investment Objective and Benchmark Index

The Biotech Growth Trust PLC seeks capital appreciation through investment in the worldwide biotechnology industry. Performance is measured against its benchmark index, the NASDAQ Biotechnology Index (sterling adjusted).

Five Year Performance (%)

Past performance is not a guide to future performance. The value of investments and the income from them may fall as well as rise and is not guaranteed; an investor may receive back less than the original amount invested.



Net Asset Value per share (total return) +96.0%

Share Price (total return) +105.9%

Benchmark: NASDAQ Biotechnology Index (sterling adjusted) +46.6%

Source: Morningstar, Index - Bloomberg.

Commentary

In November, the NAV per share was up 9.7%, the share price was up 8.1% and the benchmark NASDAQ Biotechnology Index (sterling adjusted) was up 7.7%.

Both biotechnology and the broader markets were very strong in November. We believe the market strength was driven by increasing optimism over initial Phase 3 COVID-19 vaccine data from Pfizer/BioNTech and Moderna, as well as the victory of former Vice President Joe Biden over incumbent President Donald Trump in the U.S. Presidential election. While the recent increase in COVID-19 cases worldwide continues to reach new highs daily and several territories have re-instituted lockdown procedures, investors were pleasantly surprised at the high efficacy (~95%) of mRNA-based vaccines reported in the first Phase 3 trials and expect the rapid approval and implementation of a mass vaccination program will be the first step in a safe global re-opening. Following the strongly positive vaccine data, both investors and the general public have turned their attention toward the logistics of instituting worldwide vaccinations, with much focus on the extreme cold chain storage requirements for the mRNA vaccines and the restriction of initial doses to at-risk populations. We continue to expect multiple vaccines will be required to supply the worldwide market, and estimate broader availability of vaccines for lower-risk populations starting in Spring 2021.

Following several days of absentee ballot counting, the highly anticipated U.S. Presidential election was called in favor of former Vice President Joe Biden. While incumbent President Donald Trump has not formally conceded the election and continues to take legal action based on accusations of voter fraud, we expect the presidential transition to occur as planned in January 2021. A runoff election in the State of Georgia in January will determine which party controls the U.S. Senate. Even in the event of a Democratic sweep following the runoff election, we continue to see drastic changes in healthcare legislation as unlikely given Democrats would only hold a narrow majority in the Senate.

Arcturus, Keros and Trillium were the top positive contributors to performance during the month. Arcturus shares outperformed following initial Phase 1/2 data from the company's COVID-19 mRNA vaccine, as well as readthrough from more advanced mRNA vaccines from Pfizer/BioNTech and Moderna showing very strong efficacy. We continue to view Arcturus' COVID-19 vaccine as differentiated versus competitors and anticipate vaccines from multiple companies will be required to satisfy global demand. Keros shares were strong as investors positioned ahead of additional data releases for the company's anemia portfolio compounds at a medical meeting in December. Trillium shares appreciated in anticipation of additional data from the Phase 1 trial of TTI-622, which has shown impressive clinical data to date.

Forte Biosciences, Horizon Therapeutics and Burning Rock were the largest negative contributors to performance during the month. Forte Biosciences shares were weak following the announcement of an equity financing. Shares of Horizon underperformed as monthly prescription trends of the company's key product Tepezza disappointed relative to high investor expectations. We expect continued growth from Tepezza sales in 2021 to further drive upside. Shares of Burning Rock declined from its highs in late October on no fundamental news.

Biography

Geoffrey C. Hsu, CFA, is a General Partner of OrbiMed, having joined in 2002 as a biotechnology analyst. Prior to joining OrbiMed, he worked as an analyst in the healthcare investment banking group at Lehman Brothers. Geoff received his A.B. degree summa cum laude from Harvard University and holds an M.B.A. from Harvard Business School. Prior to business school, he spent two years studying medicine at Harvard Medical School.

Portfolio Manager Profile

Portfolio management services are provided by OrbiMed Capital LLC (OrbiMed). OrbiMed is owned by six principals, including Geoff Hsu. The U.S.-based firm employs over 80 experienced investment professionals who between them have extensive scientific, medical, financial and operational expertise. They employ a bottom-up stock selection process driven by intensive proprietary research, which involves company visits and developing an understanding of commercial prospects and development programmes for individual drugs. The firm covers some 600 international pharmaceutical and biotechnology companies, two thirds of which are actively researched. OrbiMed is registered as an investment adviser under the U.S. Securities and Exchange Commission (SEC). SEC registration does not imply a certain level of skill or training.

Investment Policy

In order to achieve its investment objective, the Company invests in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis. The Company will not invest more than 15% of the value of its gross assets in any one individual stock at the time of acquisition. It will not invest more than 10% of the value of its gross assets in direct unquoted investments at the time of acquisition. This limit does not include any investment in private equity funds managed by OrbiMed or any affiliate. Up to US\$15m, after the deduction of proceeds of disposal and other returns of capital, may be invested in private equity funds managed by OrbiMed or an affiliate. The Company's borrowing policy is that borrowings will not exceed 20% of the Company's net assets. The Company may be unable to invest directly in certain countries. In these circumstances, the Company may gain exposure to companies in such countries by investing indirectly through swaps. Where the Company invests in swaps, exposure to underlying assets will not exceed 5% of the gross assets of the Company at the time of entering into the contract.

Discount / Premium Control Mechanism

The Directors have adopted an active discount management policy to establish and support an improved rating in the Company's shares through the use of share buybacks, with a view to limiting the discount to the ex income NAV per share at which the shares trade to no more than 6%. Shares bought back will be cancelled. In order to help prevent the share price trading at a significant premium to the NAV per share, the Company has the authority to issue new shares at a 1% premium to the cum income NAV per share.

The Biotech Growth Trust PLC conducts its affairs so that its shares can be recommended by independent financial advisers ("IFAs") to retail private investors. The shares are excluded from the Financial Conduct Authority's ("FCA's") restrictions which apply to non-mainstream investment products because they are shares in a UK-listed investment trust.

The Biotech Growth Trust PLC

10 Largest Holdings at 30 November 2020 (% of total investments)

Name	Total
Alexion Pharmaceuticals	4.8
Horizon Therapeutics	3.8
Neurocrine Biosciences	3.7
Turning Point Therapeutics	3.7
Keros Therapeutics	3.6
Burning Rock Biotech	2.9
Arcturus Therapeutics	2.8
Vertex Pharmaceuticals	2.7
Mirati Therapeutics	2.4
Trillium Therapeutics	2.4
Total	32.8

Geographical Breakdown as at 30 November 2020 (%)

North America	78.6%
China	8.8%
Continental Europe	6.7%
*Unquoteds	5.3%
United Kingdom	0.6%
Total	100.0%

* No more than 10% of gross assets will be invested in direct unquoted investments at the time of acquisition. The Company may also invest or commit for investment a maximum of US\$15m, after the deduction of proceeds of disposal and other returns of capital, in private equity funds managed by OrbiMed or an affiliate thereof. Of the 5.3% unquoted investments, 1.6% is classified as North America, 3.3% as China, and 0.4% as Asia.

Source: All portfolio information sourced from Frostrow Capital LLP

Discrete Performance – Calendar Years (%)

Percentage Growth	2015	2016	2017	2018	2019	YTD
NAV	15.6	-7.6	9.9	-14.3	47.4	49.0
Share Price	9.1	-4.7	12.1	-19.9	48.5	56.6
Benchmark	17.8	-6.5	10.5	-3.8	19.6	19.5

Standardised Discrete Performance (%)

Percentage Growth 12 Month Return	Nov 15- Nov 16	Nov 16- Nov 17	Nov 17- Nov 18	Nov 18- Nov 19	Nov 19- Nov 20
NAV	-3.7	6.9	-0.7	18.3	61.9
Share Price	3.6	5.1	-7.3	16.6	74.8
Index	-1.5	6.8	9.8	8.0	17.5

Past performance is not a guide to future performance. The value of investments and the income from them may fall as well as rise and is not guaranteed.

Source: NAV (total return; fully diluted) & Share Price (total return) – Morningstar. Index - Bloomberg.

Risk Warnings

This document is for information purposes only and does not constitute an offer or invitation to purchase shares in the Company and has not been prepared in connection with any such offer or invitation. Before investing in the Company, or any other investment product, you should satisfy yourself as to its suitability and the risks involved, and you may wish to consult a financial adviser.

Any return you receive depends on future market performance and is uncertain. The Company does not seek any protection from future market performance so you could lose some or all of your investment. Shares of the Company are bought and sold on the London Stock Exchange (LSE). The price you pay or receive, like other listed shares, is determined by supply and demand and may be at a discount or premium to the underlying net asset value of the Company. Usually, at any given time, the price you pay for a share will be higher than the price you could sell it. For further information on the principal risks the Company is exposed to please refer to the Company's Annual Report or Investor Disclosure Document available at www.biotechgt.com. The Company can borrow to purchase investments, this could potentially magnify any losses or gains made by the Company.

Important Information

The Biotech Growth Trust PLC is a public limited company whose shares are premium listed on the LSE and is registered with HMRC as an investment trust. The Company has an indeterminate life, although shareholders consider and vote on the continuation of the Company every five years (the next such vote will be held in 2025). This financial promotion is issued by Frostrow Capital LLP which is authorised and regulated by the Financial Conduct Authority ("FCA").

www.biotechgt.com

Fast Facts

As at 30 November 2020

Launch Date	June 1997
AIC Sector	Biotechnology & Healthcare
Date of Appointment of OrbiMed	19 May 2005
Annual Management Fee (payable by the Company)	0.65% of net assets <u>plus</u> 0.30% of market cap. <u>plus</u> £60,000
Performance fee	See Annual Report for details
Ongoing charges*	1.1%
Continuation Vote	2025 AGM and every 5th AGM thereafter
Year / Half Year	31 March / 30 September
Capital Structure	40,419,769 Ordinary Shares of 25p

Trust Characteristics

Number of Holdings	72
Total Net Assets (£m)	£607.4m
Market Capitalisation (£m)	£595.0m
Dividend Policy	It is not anticipated that the Company will pay a dividend
Gearing (AIC basis)	6.1%
Leverage	106.1%
Gross & Commitment**	
Share Price (p)	1472.00
NAV (p)	1502.71
(Discount) / Premium	(2.0%)

*Calculated at the financial year end, includes management fees and all other operating expenses, excludes performance fees.

**The Board has set the leverage limit for both the Gross and the Commitment basis at 130% of the Company's Net Asset Value.

Codes

Sedol	0038551
ISIN	GB0000385517
Legal Entity Identifier (LEI)	549300Z41EP32MI2DN29
Global Intermediary Identification Number (GIIN)	U1MQ70.99999.SL.826
Bloomberg	BIOG LN
EPIC	BIOG

How to Contact Us

Frostrow Capital LLP
25 Southampton Buildings, London, WC2A 1AL
Tel.: 0203 0084910
Fax: 0203 0438889
Website: www.frostrow.com

Email: info@frostrow.com
Twitter: @BiotechGT

